
May 20 (Reuters) - BridgeBio Pharma Inc BBIO.O:
ACORAMIDIS REDUCED INCIDENCE OF ATRIAL FIBRILLATION EVENTS IN PATIENTS WITH ATTR-CM
BRIDGEBIO PHARMA INC - ACORAMIDIS REDUCES ANNUAL CVH FREQUENCY DUE TO AF/AFL BY 43%
BRIDGEBIO PHARMA INC - ACORAMIDIS REDUCES NEW-ONSET AF/AFL INCIDENCE BY 17%
BRIDGEBIO PHARMA INC - ACORAMIDIS REDUCES ACM AND CVH EVENTS BY 42% AT MONTH 30